InSite, Bausch & Lomb deal

The companies agreed to market and manufacture INSV's PilaSite product for glaucoma, and formed a joint venture to develop INSV's DuraSite eyedrop-based drug delivery technology. Bausch & Lomb will make a $2 million equity investment in INSV, and provide up to $2 million in funding. INSV will receive royalties on sales of PilaSite. ...